Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia |
Sipetic-Grujicic, Sandra Branko
(Institute of Epidemiology, Faculty of Medicine, Belgrade University)
Murtezani, Zafir Hajdar (Clinical Hospital Centre Bezanijska Kosa) Neskovic-Konstatinovic, Zora Borivoje (Institute for Oncology and Radiology of Serbia) Marinkovic, Jelena Milutin (Institute of Medical Statistics and Informatics, Faculty of Medicine, Belgrade University) Kovcin, Vladimir Nikola (Clinical Hospital Centre Bezanijska Kosa) Andric, Zoran Gojko (Clinical Hospital Centre Bezanijska Kosa) Kostic, Sanja Vladeta (Clinical Hospital Centre Bezanijska Kosa) Ratkov, Isidora Stojan (Institute of Epidemiology, Faculty of Medicine, Belgrade University) Maksimovic, Jadranka Milutin (Institute of Epidemiology, Faculty of Medicine, Belgrade University) |
1 | Volkers N (1999). In coping with cancer, gender metters. J Natl Canver Inst, 91, 1712-4. DOI |
2 | Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW (1978). Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg, 188, 60-5. DOI |
3 | Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7. DOI ScienceOn |
4 | Giordano SH, Perkins GH, Broglio K, et al (2005). Adjuvant systemic therapy for male breast carcinoma. Cancer, 104, 2359-64. DOI ScienceOn |
5 | Guinee VF, Olsson H, Moller T, et al (1993). The prognosis of breast cancer in males. A report of 335 cases. Cancer, 71, 154-61. DOI |
6 | Joshi MG, Lee AK, Loda M, et al (1996). Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer, 77, 490-8. DOI |
7 | Lanitis S, Rice AJ, Vaughan A, et al (2008). Diagnosis and management of male breast cancer. World J Surg, 32, 2471-6. DOI |
8 | Mustafa IA, Cole B, Wanebo HJ, Bland KI, Chang HR (1998). Prognostic analysis of survival in small breast cancers. J Am Coll Surg, 186, 562-9. DOI ScienceOn |
9 | Mahdi KM, Nassiri MR, Nasiri K (2013). Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14, 3403-9. 과학기술학회마을 DOI ScienceOn |
10 | Nahleh ZA, Srikantiah R, Safa M, et al (2007). Male breast cancer in the veterans affairs population: a comparative analysis. Cancer, 109, 1471-7. DOI ScienceOn |
11 | D'Avanzo B, La Vecchia C (1995). Risk factors for male breast cancer. Br J Cancer, 71, 1359-62. DOI ScienceOn |
12 | Cimmino VM, Degnim AC, Sabel MS, et al (2004). Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol, 86, 74-7. DOI ScienceOn |
13 | Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H (2008). Male breast cancer: is the scenario changing. World J Surg Oncol, 6, 58-69. DOI ScienceOn |
14 | De Perrot M, Deleaval J, Robert J, Spiliopoulos A (2000). Thirty-year experience of surgery for breast carcinoma in men. Eur J Surg, 166, 929-31. DOI ScienceOn |
15 | Foerster R, Foerster FG, Wulff V, et al (2011). Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer, 11, 335-43. DOI |
16 | Fentiman IS, Fourquet A, Hortobagyi GN (2006). Male breast cancer. Lancet, 367, 595-604. DOI ScienceOn |
17 | Goldhirsch A, Wood WC, Coates AS, et al (2011). Panel members. Expert consensus on the primary therapy of early breast cancer. Ann Oncol, 22, 1736-47. DOI ScienceOn |
18 | Goss PE, Reid C, Pintilie M, Lim R, Miller N (1999). Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years:1955-1996. Cancer, 85, 629-39. DOI |
19 | Gomes-Raposo C, Zambrana Tevar F, Sereno Moyano M, Lopez Gomez M, Casado E (2010). Male breast cancer. Cancer Treat Rev, 36, 451-7. DOI ScienceOn |
20 | Agrawal A, Ayantunde A, Rampaul R, Robertson R (2007). Male breast cancer: a review of clinical management. Breast Cancer Res Treat, 103, 11-21. DOI |
21 | Ahmadian M, Samah AA (2013). Application of health behavior theories to breast cancer screening among Asian women. Asian Pac J Cancer Prev, 14, 4005-13. 과학기술학회마을 DOI ScienceOn |
22 | Auvien A, Curtis RE, Ron E (2002). Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst, 94, 1330-2. DOI ScienceOn |
23 | Berg JW, Hutter RV (1995). Breast cancer. Cancer, 75, 257-69. DOI |
24 | Bergmann A, Bello MA, Andrade Costa CR, et al (2012). Male breast cancer: overall survival in a single institution. J Clin Oncol, 30, 93. |
25 | Vaizey C, Burke M, Lange M (1999). Carcinoma of the male breast - a review of 91 patients from the Johannesburg Hospital breast clinics. S Afr J Surg, 37, 6-8. |
26 | Weiss JR, Moysich KB, Swede H (2005). Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 20-6. |
27 | Wolff AC, Hammond ME, Schwartz JN, et al. (2007). American society of clinical oncology/college of American pathologistsguideline recommendations for human growt factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45. |
28 | Yildirim E, Berberoglu U (1998). Male breast cancer: a 22-year experience. Eur J Surg Oncol, 24, 548-52. DOI ScienceOn |
29 | Ros JS, Fletcher JA, Linette GP, et al (2003). The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. The Oncologist, 8, 307-25. DOI ScienceOn |
30 | Omer Fatih Olmez OF, Evrensel T, Cubukcu E, et al (2013). Prognostic significance of human epidermal receptor (HER)- 3 immunohistochemical expression in patients with metastatic breast cancer. Asian Pac J Cancer Prev, 14, 4115-9. 과학기술학회마을 DOI ScienceOn |
31 | Ravandi-Kashani F, Hayes TG (1998). Male breast cancer: a review of the literature. Eur J Cancer, 34, 1341-7. DOI ScienceOn |
32 | Ribeiro G, Swindell R (1992). Adjuvant tamoxifen for male breast cancer. Br J Cancer, 65, 252-4. DOI ScienceOn |
33 | Salvadori B, Saccozzi R, Manzari A, et al (1994). Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer, 30, 930-5. DOI ScienceOn |
34 | Sasco AJ, Lowenfels AB, Pasker-de Jong P (1993). Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer, 53, 538-49. DOI ScienceOn |
35 | Slamon D, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. DOI ScienceOn |
36 | Schaub NP, Maloney N, Schneider H, Feliberti E, Perry R (2008). Changes in male breast cancer over a 30-year period. Am Surg, 74, 707-12. |
37 | Talluri S, Kakarala R, Karedan T, Kakarala M (2011). Male breast carcinoma in United States: survival rate and determinants of prognosis. J Clin Oncol, 29, 32. DOI ScienceOn |
38 | Thompson D, Duedal S, Kirner J, et al (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst, 97, 813-22. DOI ScienceOn |
39 | Bruce DM, Heyes SD, Payne S (1996). Male breast cancer: clinicopathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol, 22, 42-6. DOI ScienceOn |
40 | Xu CY, Jiang ZN, Zhou Y, Li JJ, Huang LM (2013). Estrogen receptor roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049-52. 과학기술학회마을 DOI ScienceOn |
41 | Early Breast Cancer Trialist Collaborative group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 365, 1687-717. DOI ScienceOn |